Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
|
|
Viracta Therapeutics, Inc. (VIRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/16/2023 |
3
| Cohen Darrel P. (Chief Medical Officer) has filed a Form 3 on Viracta Therapeutics, Inc. |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"Viracta Therapeutics, Inc. Selected Balance Sheet Highlights June 30, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 72,867 $ 91,043 Total assets $ 76,859 $ 95,991 Total liabilities $ 36,077 $ 34,888 Stockholders' equity $ 40,782 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 8,197 $ 6,324 $ 15,804 $ 12,420 General and administrative 4,253 4,181 8,853 8,517 Total operating expenses 12,450 10,505 24,657 20,937 Loss from operations Total other expense Net loss Unrealized gain on short-term investments — 63 — Comprehensive loss Net loss per share, basic and diluted $ $ $ $ Weight..." |
|
| 08/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/09/2023 |
4
| Simon Barry J. (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| Rubino Stephen (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| ROYSTON IVOR (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| Pomerantz Roger (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| Murphy Samuel Lafayette (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| DARCY THOMAS E (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| Chung Jane (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| Borellini Flavia (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
4
| Barlow Jane F (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $1.5, valued at
$60k
|
|
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/26/2023 |
4
| ROYSTON IVOR (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Exercised 25,219 restricted stock units
@ $0 |
|
| 05/26/2023 |
4
| Pomerantz Roger (Director) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Exercised 9,035 restricted stock units
@ $0 |
|
| 05/26/2023 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Sold 3,635 shares
@ $1.4196, valued at
$5.2k
Exercised 6,889 restricted stock units
@ $0 |
|
| 05/26/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"-- Financial tables attached – Viracta Therapeutics, Inc. Selected Balance Sheet Highlights March 31, December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 80,332 $ 91,043 Total assets $ 85,781 $ 95,991 Total liabilities $ 34,668 $ 34,888 Stockholders' equity $ 51,113 $ 61,103 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 7,607 $ 6,096 General and administrative 4,600 4,336 Total operating expenses 12,207 10,432 Loss from operations Total other expense Net loss Unrealized gain on short-term investments 91 — Comprehensive loss Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 3..." |
|
| 05/05/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"8-K/A",
"CONSULTING AGREEMENT This consulting agreement is made by and between VIRACTA THERAPEUTICS, INC., having a place of business at 2533 South Coast Hwy 101, Suite 210, Cardiff, CA 92007 USA, together with its affiliates and Lisa Rojkjaer, M.D., an individual with a place of business at [***] , effective on the 5th day of May, 2023 at 4:59pm PDT for the purpose of setting forth the exclusive terms and conditions by which Company will acquire Consultant's services on a temporary basis. 1. WORK AND PAYMENT. Attached to this Agreement as is a project assignment describing the work Consultant will perform . This Project Assignment, and any future Project Assignment, will be subject to the terms and conditions of this Agreement and will set forth at a minimum the following terms: Consultant's rate ..." |
|
| 05/02/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/31/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/17/2023 |
4
| Rothera Mark (President and CEO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 400,000 options to buy
@ $1.65, valued at
$660k
|
|
| 03/17/2023 |
4
| Rojkjaer Lisa (Chief Medical Officer) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 150,000 options to buy
@ $1.65, valued at
$247.5k
|
|
| 03/17/2023 |
4
| Chevallard Daniel R. (CFO and COO) has filed a Form 4 on Viracta Therapeutics, Inc.|
Txns:
| Granted 200,000 options to buy
@ $1.65, valued at
$330k
|
|
| 03/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
8-K
| Quarterly results|
Docs:
|
"Viracta Therapeutics, Inc. Selected Balance Sheet Highlights December 31, 2022 2021 Cash, cash equivalents and short-term investments $ 91,043 $ 103,554 Total assets $ 95,991 $ 108,552 Total liabilities $ 34,888 $ 14,181stockholders' equity $ 61,103 $ 94,371 Viracta Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 6,703 $ 7,303 $ 26,262 $ 23,861 Purchased and acquired in-process research and development — — — 88,478 General and administrative 4,871 4,015 24,327 15,437 Total operating expenses 11,574 11,318 50,589 127,776 Gain on Royalty Purchase Agreement — — — 13,500 Loss from operations Total other income 1,248 1,392 Net loss..." |
|
|
|
|